Boston Scientific brings on Abiomed exec as investor relations head; EU device reg revamp creates apprehension;

@FierceMedDev: Myriad partners up with BioMarin for cancer diagnostics. Yesterday's story | Follow @FierceMedDev

@MarkHFierce: OraSure dumped Roche in favor of Thermo Fisher for a drug testing Dx development deal. Strategic, not fickle. Yesterday's story | Follow @MarkHFierce

@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

> Boston Scientific ($BSX) hired a veteran Abiomed ($ABMD) executive to be its new vice president of investor relations. Item

> Fisher & Paykel Healthcare, a New Zealand medical equipment manufacturer, reported record profit and higher revenues for the first half of its fiscal year. Item

> NeuroMetrix ($NURO) debuted a new website designed to help convey information to physicians and patients about chronic pain and the company's signature nerve stimulation device designed to address it. Item

> Finland's BonAlive Biomaterials gained a CE mark for the new ready-to-use moldable version of its osteostimulative bioactive glass bone regeneration putty. Item

> OrthoSensor will use Valtronic to manufacture its Verasense intelligent knee system. Item

> Observers are getting anxious about final efforts to revamp Europe's medical device regulations. Item

Biotech News

@FierceBiotech: Avalon jumpstarts first biotech in $500M GlaxoSmithKline portfolio deal. Article | Follow @FierceBiotech

@JohnCFierce: Lots of biotech startup news this month. Lots of deal flow in the pipeline. | Follow @JohnCFierce

@DamianFierce: Meet LEE011, Novartis's overnight celebrity breast cancer candidate. News | Follow @DamianFierce

@EmilyMFierce: Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. Story | Follow @EmilyMFierce

> Regeneron, Sanofi hit a trio of goals in first PhIII test of rheumatoid arthritis drug. Story

> Novartis sneaks up on Pfizer with CDK4/6 cancer challenger. Article

> Food allergy startup bags $17M for oral immunotherapy. News

Pharma News

@FiercePharma: Thursday's best-read special report: Top 10 Patent Losses of 2014. Report | Follow @FiercePharma

@EricPFierce: Pfizer says it will close a Puerto Rico plant days after Merck says the same thing. Story | Follow @EricPFierce

@CarlyHFierce: Biogen Idec's MS pill Tecfidera wins 10 years' protection in EU. Analysts expect 36% of $4.5B in 2018 sales to come from non-U.S. More | Follow @CarlyHFierce

> Ariad's Iclusig further restricted by EMA. Story

> Novartis plans $5B share buyback, hints at restructuring. Article

> EU patent call sets stage for Tecfidera launch in Europe. Report

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.